"Through one of its subsidiaries, Merck (NYSE: MRK) has proposed a takeover of Viralytics for A$1.75 per share after market close in Australia, with Viralytics shares finishing down around 2% at $0.615 per share at the closing bell.
"Merck has opted to pay a 160% premium to the one month volume weighted average price (VWAP) for Viralytics primarily due of its lead development candidateCAVATAK, a clinical-stage immunotherapy with strong potential to treat several different cancers including melanomas."
You just never know.
https://**promotion blocked**.com.au/merck-breakthrough-oncolytic-immunotherapy-developer-viralytics/
How would you have felt selling on the day before at 61.5c! to see $1.75 next morning CASH.
So in fact whilst it was 160% on VWAP, it was 184.5% on the close
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.3¢ |
Change
0.008(4.84%) |
Mkt cap ! $35.02M | |||
| Open | High | Low | Value | Volume |
| 15.5¢ | 16.3¢ | 15.5¢ | $7.823K | 49.85K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 364873 | 16.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.5¢ | 60867 | 3 |
View Market Depth
| Last trade - 12.33pm 27/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |